Stereocontrolled Oligonucleotides for Nucleic Acid Therapeutics: A Perspective

Crooke ST. (1999). Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta, 1489:31–44.

Deleavey GF and Damha MJ . (2012). Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol, 19:937–954.

Eckstein F . (1967). A dinucleoside phosphorothioate. Tetrahedron Lett, 8:1157–1160.

Eckstein F . (2000). Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev, 10:117–121.

Agrawal S , Goodchild J , Civeira MP , Thornton AH , Sarin PS and Zamecnik PC . (1988). Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A, 85:7079–7083.

Cohen JS. (1991). Oligonucleotides as therapeutic agents. Pharmacol Ther, 52:211–225.

Roehr B . (1998). Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care, 4:14–16.

Mipomersen label. (n.d.). (2013). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203568s000lbl.pdf

Inotersen label. (n.d.). (2018). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf

Waylivra. (n.d.). (2019). Retrieved from https://www.medicines.org.uk/emc/files/pil.10636.pdf

Nusinersen label. (n.d.). (2018). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209531s003s004lbl.pdf

Kumar H , Goel A , Chand N , Bhushan B , Chander R and Goel. A (2010). To compare the clinical efficacy and safety of salbutamol and levosalbutamol metered-dose inhalers in patients of bronchial asthma. Chest, 138:160A.

Ito T , Ando H , Suzuki T , Ogura T , Hotta K , Imamura Y , Yamaguchi Y and Handa H . (2010). Identification of a primary target of thalidomide teratogenicity. Science, 327:1345–1350.

Mori T , Ito T , Liu S , Ando H , Sakamoto S , Yamaguchi Y , Tokunaga E , Shibata N , Handa H and Hakoshima. T (2018). Structural basis of thalidomide enantiomer binding to cereblon. Sci Rep, 8:1294.

Tokunaga E , Yamamoto T , Ito E and Shibata. N (2018). Understanding the thalidomide chirality in biological processes by the self-disproportionation of enantiomers. Sci Rep, 8:17131.

Stec WJ and Wilk A . (1994). Stereocontrolled Synthesis of Oligo(nucleoside phosphorothioate)s. Angew Chem Int Ed Engl, 33:709–722.

Iwamoto N , Oka N , Sato T and Wada T . (2009). Stereocontrolled solid-phase synthesis of oligonucleosideH-phosphonates by an oxazaphospholidine approach. Angew Chem Int Ed Engl, 48:496–499.

Krieg AM , Guga P and Stec W . (2003). P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides, 13:491–499.

Koziolkiewicz M , Krakowiak A , Kwinkowski M , Boczkowska M and Stec WJ . (1995). Stereodifferentiation—the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res, 23:5000–5005.

Yu D , Kandimalla ER , Roskey A , Zhao Q , Chen L , Chen J and Agrawal S . (2000). Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. Bioorg Med Chem, 8:275–284.

Jahns H , Roos M , Imig J , Baumann F , Wang Y , Gilmour R and Hall. J (2015). Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs. Nat Commun, 6:6317.

Iwamoto N , Butler DC , Svrzikapa N , Mohapatra S , Zlatev I , Sah DW , Standley SM , Lu G , Apponi LH , et al. (2017). Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol, 35:845–851.

Butler D , Iwamoto N , Meena M , Svrzikapa N , Verdine GL and Zlatev I . (2015). Chiral Control. United States Patent, 2015/0211006. A1.

Nowotny M , Gaidamakov SA , Ghirlando R , Cerritelli SM , Crouch RJ and Yang W . (2007). Structure of Human RNase H1 Complexed with an RNA/DNA Hybrid: insight into HIV Reverse Transcription. Mol Cell, 28:264–276.

Meena M , Butler D , Iwamoto N , Svrzikapa N , Verdine GL and Zlatev. I (2015, July 23). Chiral Design. International Application Published under PCT, WO, 2015/107425 A2.

Meena. (2017). Preclinical Studies of WVE-120101 and WVE-120102, Investigational Stereopure ASOs for Huntington's Disease (HD). Presented at the DIA/FDA Oligonucleotide Meeting, Washington, DC.

Panzara M . (2019). Selective Targeting of Mutant Huntingtin Using Stereopure Oligonucleotides as a Potential Therapeutic Approach for Huntington's Disease. Presented at the ASGCT, Washington, DC.

Liu W , Chaurette J , Pfister EL , Kennington LA , Chase KO , Bullock J , Vonsattel JP , Faull RL , Macdonald D , et al. (2013). Increased steady-state mutant Huntingtin mRNA in Huntington's disease brain. J Huntingtons Dis, 2:491–500.

Southwell AL , Skotte NH , Kordasiewicz HB , ME Østergaard, Watt AT , Carroll JB , Doty CN , Villanueva EB , Petoukhov E , et al. (2014). In vivo evaluation of candidate allele-specific mutant Huntingtin gene silencing antisense oligonucleotides. Mol Ther, 22:2093–2106.

Kordasiewicz HB , Stanek LM , Wancewicz EV , Mazur C , McAlonis MM , Pytel KA , Artates JW , Weiss A , Cheng SH , et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of Huntingtin synthesis. Neuron, 74:1031–1044.

Kourkouta E , Weij R , González-Barriga A , Mulder M , Verheul R , Bosgra S , Groenendaal B , Puoliväli J , Toivanen J , et al. (2019). Suppression of mutant protein expression in Spinocerebellar Ataxia type 3 and type 1 mice using a CAG repeat-targeting antisense oligonucleotide. Mol Ther Nucleic Acids, 17:601–614.

Gagnon KT , Pendergraff HM , Deleavey GF , Swayze EE , Potier P , Randolph J , Roesch EB , Chattopadhyaya J , Damha MJ , et al. (2010). Allele-selective inhibition of mutant Huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry, 49:10166–10178.

Migawa MT , Shen W , Wan WB , Vasquez G , Oestergaard ME , Low A , De Hoyos CL , Gupta R , Murray S , et al. (2019). Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Res, 47:5465–5479.

Østergaard ME , De Hoyos CL , Wan WB , Shen W , Low A , Berdeja A , Vasquez G , Murray S , Migawa MT , et al. (2020). Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Res, 48:1691–1700.

Hagedorn PH , Persson R , Funder ED , Albaek N , Diemer SL , Hansen DJ , Møller MR , Papargyri N , Christiansen H , et al. (2018). Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov Today, 23:101–114.

Li M , Lightfoot HL , Halloy F , Malinowska AL , Berk C , Behera A , Schümperli D and Hall J . (2016). Synthesis and cellular activity of stereochemically-pure 2′-O-(2-methoxyethyl)-phosphorothioate oligonucleotides. Hem Commun (Camb), 53:541–544.

Funder ED , Albaek N , Moisan A , Sewing S and Koch. T (2020). Refining LNA safety profile by controlling phosphorothioate stereochemistry. PLoS One, 15:e0232603.

Wan WB , Migawa MT , Vasquez G , Murray HM , Nichols JG , Gaus H , Berdeja A , Lee S , Hart CE , et al. (2014). Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res, 42:13456–13468.

Knouse KW , deGruyter JN , Schmidt MA , Zheng B , Vantourout JC , Kingston C , Mercer SE , McDonald IM , Olson RE , et al. (2018). Unlocking P(V): reagents for chiral phosphorothioate synthesis. Science, 361:1234–1238.

Corporate presentation. (2018). Cambridge, MA: Wave Life Sciences. https://ir.wavelifesciences.com/static-files/ffb627ab-f41e-48c6-9081-6b880ab74fe0

Structure of Suvodirsen. (n.d.). (2019). Retrieved from https://chem.nlm.nih.gov/chemidplus/rn/2095270-67-8

Panzara M . (2020). Analysis of the Phase 1 Open—Label Extension Study of Suvodirsen in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping. Presented at the 2020 Muscular Dystrophy Association Conference was Virtual. online.

Goemans N , Mercuri E , Belousova E , Komaki H , Dubrovsky A , McDonald CM , Kraus JE , Lourbakos A , Lin Z , et al. (2018). A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul Disord, 28:4–15.